PMID- 15529575
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20171116
IS  - 1220-4749 (Print)
IS  - 1220-4749 (Linking)
VI  - 38-39
DP  - 2000-2001
TI  - Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus.
PG  - 83-8
AB  - In our study we have investigated the presence of apoptotic bodies, soluble FAS 
      receptor and TNF (tumor necrosis factor) in three clinical forms of lupus 
      erythematosus. Determinations were performed in attack period of: systemic lupus 
      erythematosus (SLE) for 20 patients, 20 patients with subacute cutaneous lupus 
      erythematosus (SCLE), 20 patients with chronic discoid lupus erythematosus (DLE). 
      Determinations were performed by ELISA (for apoptotic bodies, kit Boehringer, 
      normal values 400-800 mU), (for sFAS, kit R&D Systems, normal values 4500-17000 
      pg/ml) (for TNF, ELISA kit R&D Systems, normal values 0.4-3.6 pg/ml). Results in 
      SLE: apoptotic bodies were increased in 16 cases (980-1030); sFAS in 18 cases 
      (17000-24000 pg/ml) TNF was increased in all 20 cases (40-140 pg/ml). In SCLE 
      with multiple cutaneous lesions and without internal organs disturbance the 
      apoptotic bodies were increased in 10 cases (960-1030 pg/ml), sFAS in 9 cases 
      (17000-22000 pg/ml), and TNF alpha in 9 cases. In DLE, apoptotic bodies were 
      increased in 2 patients (980-1010 pg/ml), sFAS in 3 patients (17000-20000 pg/ml) 
      and TNF in 2 patients (20-40 pg/mil). Investigated values were slightly 
      correlated with immune parameters (anti dsDNA antibodies), but they were 
      correlated with the presence of renal disturbances or extension of cutaneous 
      lesions. We consider that the presence of increased apoptotic bodies as a result 
      of peripheral mononuclear cells apoptosis appear as a nauto-limiting mechanism in 
      a pathological immune response. The increase of sFAS in lupus patients serum 
      might be interpreted as an alteration of apoptosis respectively a deficit in 
      apoptosis which has as a first consequence the persistence of B and T 
      lymphocytes, activated, in the pathogen immune response.
FAU - Alecu, M
AU  - Alecu M
AD  - Dermatological Reaseach Center, Scarlat Longhin Hospital for Dermatology, 216, 
      Sos. Serban Voda, 73202, Bucharest, Romania.
FAU - Coman, G
AU  - Coman G
FAU - Alecu, S
AU  - Alecu S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Rom J Intern Med
JT  - Romanian journal of internal medicine = Revue roumaine de medecine interne
JID - 9304507
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (fas Receptor)
SB  - IM
MH  - Apoptosis/physiology
MH  - Chronic Disease
MH  - Humans
MH  - Lupus Erythematosus, Discoid/*blood/physiopathology
MH  - Lupus Erythematosus, Systemic/*blood/physiopathology
MH  - Tumor Necrosis Factor-alpha/*analysis
MH  - fas Receptor/*blood
EDAT- 2004/11/09 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/11/09 09:00
PHST- 2004/11/09 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/11/09 09:00 [entrez]
PST - ppublish
SO  - Rom J Intern Med. 2000-2001;38-39:83-8.